Clinical Trials Browser

OTHER × Interventional × ensartinib × Clear all

NCT07354061 2026-04-01

TD-ENSEMBLE

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04837716 2026-02-19

Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03420508 2026-02-05

Treating Patients With Melanoma and ALK Alterations With Ensartinib

Phase 2 Active not recruiting

Melanoma

NCT07235306 2025-11-19

Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06955325 2025-05-06

UPLIFT

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06785584 2025-01-21

Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study

Phase 4 Not yet recruiting

ALK-positive Advanced NSCLC

NCT06779539 2025-01-17

Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06780839 2025-01-17

Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06762327 2025-01-07

Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer

Phase 2 Not yet recruiting

Other solid neoplasm

Solid Tumors

NCT06563999 2024-12-10

NUMER

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05491811 2024-09-19

EAGLE

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05241028 2023-10-10

Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03574402 2022-12-06

TRUMP

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02898116 2022-10-10

Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer

Phase 1/2 Completed

2 enrolled 8 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT05380024 2022-08-18

A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05186506 2022-01-11

A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05178511 2022-01-05

ERSGATR

Phase 2 Unknown

The Diagnosis Was ALK Positive NSCLC